Coleman K. Obasaju, MD, PhD, is the global leader for diversity in clinical research, global medical affairs leader for Erbitux and Necitumumab and had responsibility for the US Medical Liaisons in the Oncology Business Unit (OBU) of Eli Lilly.
Dr. Obasaju received his doctor of medicine degree at the University College Hospital, Ibadan, Nigeria. He then went on to pursue postgraduate training in clinical pharmacology and medical oncology in England at the Christie Hospital and the University of Manchester, obtaining both a master’s and a doctorate degree.
A former Audrey Meyer Mars oncology fellow, Dr. Obasaju completed an internal medicine residency program at the University of Pennsylvania Health Systems and then went on to a combined fellowship in medical oncology/hematology in the United States at Fox Chase Cancer Center and Temple University Cancer Hospital, both in Philadelphia. He obtained a clinical investigator training program fellowship awarded by the National Cancer Institute prior to joining Eli Lilly and Company in 2001.
Additionally, Dr. Obasaju served for four years as a member of the American Association for Cancer Research Minority in Cancer Research Council. In that role, he provided more visibility to the scientific contribution of minority scientists and developed strategies to improve the pipeline of future minority investigators.
Dr. Obasaju has given multiple presentations in national and international forums and is the author of numerous publications in peer-reviewed journals.
In 2013, Dr. Obasaju was awarded the prestigious Scroll of Merit for outstanding work in the field of medicine, and specifically for his dedication and tenacious efforts in clinical research and untiring focus on increasing minority participation in clinical trials.
When Dr. Coleman Obasaju started working in clinical trial development at Lilly, he was shocked to see the poor representation of minorities in clinical trials in the entire industry, even for diseases from which minorities suffer disproportionately.
Obasaju rang the alarm bells in Lilly Oncology, where several other individuals were aligned with his passion and vision to have clinical test groups better match the disease prevalence rate in the general population.